Dr. Yu Discusses Optimal Testosterone Suppression

Partner | Cancer Centers | <b>SCCA</b>

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

There is more and more data to show that lower testosterone levels are optimal. It is currently known that LHRH agonists work well and produce similar clinical outcomes to orchiectomy, but testosterone is not lowered as well and testosterone escapes can occur.

Researchers conducted this analysis to determine the effect on testosterone and free testosterone in patients that underwent orchiectomy. Yu says this is a descriptive study meant to define what testosterone/free testosterone levels would be in a patient who had optimal androgen deprivation therapy (which would be orchiectomy).